RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics
Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "RNA Interference Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering.
Global RNA Interference Therapeutics Market to Reach USD 31.4 Billion by 2035
The global RNA interference therapeutics market was valued at USD 4.2 billion in 2025 and is projected to reach USD 31.4 billion by 2035, expanding at a compound annual growth rate (CAGR) of 18.5% during the forecast period.
Market growth is being driven by advances in genetic research, the rising prevalence of rare and chronic diseases, and increased investment in precision medicine. Continued innovation in molecular design, RNA delivery systems, conjugation technologies, and therapeutic targeting is improving the stability, efficacy, and safety of RNAi-based treatments. These developments are supporting broader clinical applications across genetic, metabolic, cardiovascular, hepatic, and other complex disease areas.
Pharmaceutical and biotechnology companies are expanding RNA-based research programs and clinical pipelines to address previously difficult-to-treat conditions. Regulatory support for orphan drugs and precision medicines is also creating favorable development and commercialization opportunities. In parallel, strategic collaborations among drug developers, academic institutions, biotechnology companies, and research organizations are accelerating clinical progress and helping reduce development timelines.
Hereditary Transthyretin-Mediated Amyloidosis Leads by Indication
The hereditary transthyretin-mediated amyloidosis (hATTR) segment accounted for 35.7% of the global RNA interference therapeutics market in 2025 and is expected to reach USD 10.9 billion by 2035. Segment leadership is supported by improving diagnostic rates, growing clinical awareness, and the availability of approved RNAi therapies. Increased adoption of targeted treatments and continued research into hATTR management are expected to sustain demand throughout the forecast period.
Subcutaneous Administration Supports Patient-Centric Treatment
The subcutaneous administration segment is forecast to expand at a CAGR of 18.6% through 2035. This route continues to gain preference because of its convenience, reduced dependence on clinical supervision, and potential to improve treatment adherence compared with intravenous administration.
Advances in conjugation and targeted delivery technologies have strengthened the clinical viability of subcutaneous RNAi therapies. Improved tissue targeting and lower systemic exposure may enhance therapeutic performance while supporting more manageable treatment schedules. These benefits are expected to reinforce the segment's position within the global RNA interference therapeutics market.
North America Maintains Global Market Leadership
North America held 72% of the RNA interference therapeutics market in 2025. The region's dominant position is attributed to advanced healthcare infrastructure, strong clinical adoption, early access to approved RNAi medicines, and regulatory frameworks that support rare disease and precision medicine development.
A well-established biotechnology ecosystem, significant investment in genetic research, and expanding clinical trial capabilities further strengthen the North American market. The presence of leading pharmaceutical and biotechnology companies also supports product development, regulatory submissions, manufacturing expansion, and commercialization across the United States and Canada.
Competitive Landscape and Company Strategies
Major companies operating in the global RNA interference therapeutics market include Novartis, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Sanofi, Novo Nordisk, Silence Therapeutics, Sirnaomics, Arbutus Biopharma, Benitec Biopharma, OliX Pharmaceuticals, and Atalanta Therapeutics.
Market participants are investing in proprietary RNA technology platforms, advanced delivery systems, precision medicine programs, and next-generation molecular design. Companies are also broadening clinical pipelines across multiple disease areas while pursuing partnerships, licensing agreements, and research collaborations to strengthen innovation and improve development efficiency.
Additional competitive priorities include scaling manufacturing capacity, maintaining consistent product quality, securing regulatory approvals, and expanding into international markets. Investment in targeted delivery technologies is expected to remain central to differentiation as companies seek to improve efficacy, stability, dosing convenience, and targeting accuracy. These strategies will shape long-term competition and support continued growth across the RNA interference therapeutics industry.
Comprehensive Market Analysis and Forecast
Key Topics Covered:
Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Research approach
1.3 Quality commitments
1.3.1 GMI AI policy and data integrity commitment
1.3.1.1 Source consistency protocol
1.4 Research trail and confidence scoring
1.4.1 Research trail components
1.4.2 Scoring components
1.5 Data collection
1.5.1 Partial list of primary sources
1.6 Data mining sources
1.6.1 Paid sources
1.6.1.1 Sources, by region
1.7 Base estimates and calculations
1.7.1 Revenue share analysis
1.7.2 Base year calculation
1.8 Forecast model
1.9 Research transparency addendum
1.9.1 Source attribution framework
1.9.2 Quality assurance metrics
1.9.3 Our commitment to trust
Chapter 2 Executive Summary
2.1 Industry 360 synopsis
2.2 Key market trends
2.2.1 Regional trends
2.2.2 Indication trends
2.2.3 Route of administration trends
2.2.4 End use trends
2.3 CXO perspectives: Strategic imperatives
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of genetic disorders
3.2.1.2 Advancements in RNA delivery technologies
3.2.1.3 Rising investment in RNAi-based research
3.2.1.4 Approval of RNAi therapeutics for chronic and rare diseases
3.2.2 Industry pitfalls and challenges
3.2.2.1 Challenges in effective delivery of RNAi molecules
3.2.2.2 High cost of RNAi therapeutics development
3.2.3 Market opportunities
3.2.3.1 RNAi applications in neurology and neurodegenerative diseases
3.2.3.2 Personalized RNAi therapies for genetic diseases
3.3 Growth potential analysis
3.4 Technology landscape
3.4.1 Current technology
3.4.2 Emerging technologies
3.5 Regulatory landscape (Driven by primary research)
3.5.1 North America
3.5.2 Europe
3.5.3 Asia-Pacific
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Pipeline analysis (Driven by primary research)
3.9 Impact of AI and generative AI on the market (Driven by primary research)
3.10 Future market trends (Driven by primary research)
Chapter 4 Competitive Landscape, 2025
4.1 Introduction
4.2 Company market share analysis
4.2.1 North America
4.2.2 Europe
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Merger and acquisition
4.6.2 Partnership and collaboration
4.6.3 New product launches
4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, by Indication, 2022-2035 ($ Mn)
5.1 Key trends
5.2 Hereditary transthyretin-mediated amyloidosis (hATTR)
5.3 Transthyretin amyloidosis with cardiomyopathy (ATTR-CM)
5.4 Acute hepatic porphyria (AHP)
5.5 Primary hyperoxaluria type 1 (PH1)
5.6 Hypercholesterolemia / Dyslipidemia
5.7 Familial chylomicronemia syndrome (FCS)
Chapter 6 Market Estimates and Forecast, by Route of Administration, 2022-2035 ($ Mn)
6.1 Key trends
6.2 Subcutaneous (SC)
6.3 Intravenous (IV)
Chapter 7 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Specialty treatment centers
7.4 Clinics
Chapter 8 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.4 Asia-Pacific
8.4.1 China
8.4.2 India
8.4.3 Japan
8.4.4 Australia
8.4.5 South Korea
8.5 Rest of the world
Chapter 9 Company Profiles
9.1 Commercial players
9.1.1 Alnylam Pharmaceuticals
9.1.2 Novartis
9.1.3 Novo Nordisk
9.1.4 Sanofi
9.1.5 Arrowhead Pharmaceuticals
9.2 Emerging/ pipeline players
9.2.1 Silence Therapeutics
9.2.2 Sirnaomics
9.2.3 Arbutus Biopharma
9.2.4 Benitec Biopharma
9.2.5 OliX Pharmaceuticals
9.2.6 Atalanta Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/hz3fhd
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.